PulmoSIM Therapeutics
PulmoSIM Therapeutics is the pharmaceutical brand of VeriSIM Life focused on developing breakthrough therapies for rare and progressive respiratory diseases such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The company aims to improve patient outcomes and quality of life by targeting the underlying biology of these diseases to reduce the need for combination therapies. PulmoSIM leverages BIOiSIM, an AI bio-simulation platform developed by VeriSIM Life, to accelerate drug development by bridging the translational gap between preclinical and clinical phases.
PulmoSIM Therapeutics
PulmoSIM Therapeutics is the pharmaceutical brand of VeriSIM Life focused on developing breakthrough therapies for rare and progressive respiratory diseases such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The company aims to improve patient outcomes and quality of life by targeting the underlying biology of these diseases to reduce the need for combination therapies. PulmoSIM leverages BIOiSIM, an AI bio-simulation platform developed by VeriSIM Life, to accelerate drug development by bridging the translational gap between preclinical and clinical phases.